+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease



CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease



Blood 99(3): 1023-1029



Although the presence or absence of somatic mutations in the immunoglobulin variable region (IgV(H)) genes in chronic lymphocytic leukemia (B-CLL) identifies subtypes with very different prognoses, the assay is technically complex and unavailable to most laboratories. CD38 expression has been suggested as a surrogate marker for the 2 subtypes. IgV(H) mutations and CD38 expression in 145 patients with B-CLL with a long follow-up were compared. The 2 assays gave discordant results in 41 patients (28.3%). Multivariate analysis demonstrated that Binet stage, IgV(H) mutations and CD38 were independent prognostic indicators. Median survival time in patients whose cells had unmutated IgV(H) genes and expressed CD38 was 8 years; in those with mutated IgV(H) genes not expressing CD38, it was 26 years. For those with discordant results, median survival time was 15 years. Thus, although CD38 expression does not identify the same 2 subsets as IgV(H) mutations in CLL, it is an independent risk factor that can be used with IgV(H) mutations and clinical stage to select patients with B-CLL with the worst prognoses. Using cryopreserved cells taken at intervals during the course of the disease, however, changes of CD38 expression over time were demonstrated in 10 of 41 patients. Causes of the variation of CD38 expression require further study. Additional prospective studies are required for comparing CD38 expression with other prognostic factors and for taking sequential measurements during the course of the disease.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010263042

Download citation: RISBibTeXText

PMID: 11807008


Related references

CD38 expression and IgV gene mutations are independent prognostic factors in chronic lymphocytic leukaemia and can be used to select stage A patients for treatment. British Journal of Haematology 113(Suppl. 1): 62, 2001

Gene Expression Profiling in CD38+ Versus CD38- B Cell Chronic Lymphocytic Leukemia. Blood 100(11): Abstract No 1480, 2002

Highly purified CD38(+) and CD38(-) sub-clones derived from the same chronic lymphocytic leukemia patient have distinct gene expression signatures despite their monoclonal origin. Leukemia 21(4): 687-696, 2007

Immunoglobulin V(H) genes and CD38 expression analysis in B-cell chronic lymphocytic leukemia. Acta Haematologica 116(1): 72-74, 2006

Immunoglobulin V genes and CD38 expression analysis in B-cell chronic lymphocytic leukemia. Blood 97(6): 1893-1894, 2001

The Prognostic Significance of Combaind Expression of Zap-70 and Cd38 in Chronic Lymphocytic Leukemia. Georgian Medical News 2017(267): 12-16, 2017

The Prognostic Significance of Combined Expression of ZAP-70 and CD38 in Chronic Lymphocytic Leukemia. Journal of the Egyptian National Cancer Institute 21(4): 287-297, 2009

The prognostic value of CD38 expression and its quantification in B cell chronic lymphocytic leukemia (B-CLL). Leukemia and Lymphoma 45(3): 455-462, 2004

CD38 Expression and Variation as a Prognostic Factor Chronic Lymphocytic Leukemia. Clinical Laboratory 62(7): 1287-1293, 2016

Lack of correlation between immunoglobulin somatic mutation and expression of CD38 in chronic lymphocytic leukemia. Blood 96(11 Part 1): 367a, 2000

Analysis of immunoglobulin VH genes in relation to CD38 expression in B cell chronic lymphocytic leukemia. Blood 96(11 Part 1): 716a, 2000

CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 98(1): 181-186, 2001

CD38 expression identifies two distinct prognostic subsets in B-chronic lymphocytic leukemia. Blood 96(11 Part 1): 366a-367a, 2000

The use of CD38 expression by monoclonal B lymphocytes as a prognostic factor in B-cell chronic lymphocytic leukemia. Journal of Biological Regulators and Homeostatic Agents 18(3-4): 340-346, 2005

Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94(6): 1840-1847, 1999